Ann: Results of First Court Hearing, page-35

In the notice it states that in the final IER:

In reaching its conclusion, the Independent Expert has taken into account all relevant matters including the results of the Data Confirmation Study, the FDA’s grant of 510(k) clearance for SleepCheckRx in the United States and the extension of the Medgate AG licence.
​

The final report placed the same valuation on the company as in the draft report which issued on 30 May 2022.  How could the valuation of the company not have changed when the 510(k) approval was received on 5 July, the Australian patent was only granted on 23 June and the Japanese patent was granted on 22 June (Bear in mind RAP's agreements with AstraZeneca are for Japan so the issue of the Japanese patent further derisks the company with a pharma giant being involved to assist in defending the patent if necessary), i.e. all occurrences being after issuance of the draft report?  I have no idea when the Medgate licence extension was notified to RAP but I have no doubt that it was after 30 May!!

Something is not right if none of these significant events moves the valuation of the company upwards.  

Not happy Jan and will definitely be attending the meeting in person!!!